Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development

ABSTRACTMechanistic PKPD models are now advocated not only by academic and industrial researchers, but also by regulators. A recent development in this area is based on the growing realisation that innovation could be dramatically catalysed by creating synergy at the interface between Systems Biology and PKPD, two disciplines which until now have largely existed in ‘parallel universes’ with a limited track record of impactful collaboration. This has led to the emergence of systems pharmacology. Broadly speaking, this is the quantitative analysis of the dynamic interactions between drug(s) and a biological system to understand the behaviour of the system as a whole, as opposed to the behaviour of its individual constituents; thus, it has become the interface between PKPD and systems biology. It applies the concepts of Systems Engineering, Systems Biology, and PKPD to the study of complex biological systems through iteration between computational and/or mathematical modelling and experimentation. Application of systems pharmacology can now impact across all stages of drug research and development, ranging from very early discovery programs to large-scale Phase 3/4 patient studies, and has the potential to become an integral component of a new ‘enhanced quantitative drug discovery and development’ (EQD3) R&D paradigm.

[1]  O. Jensen.  Modification-specific proteomics: characterization of post-translational modifications by mass spectrometry. , 2004, Current opinion in chemical biology.

[2]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[3]  M. Danhof,et al.  Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling—A New Classification of Biomarkers , 2005, Pharmaceutical Research.

[4]  Paul J. Williams,et al.  Pharmacometrics: Impacting Drug Development and Pharmacotherapy , 2006 .

[5]  M. Danhof,et al.  5.38 – Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling for the Prediction of In Vivo Drug Concentration–Effect Relationships – Application in Drug Candidate Selection and Lead Optimization , 2007 .

[6]  Steven W. Martin,et al.  The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics. , 2007, Drug discovery today.

[7]  Ene I. Ette,et al.  Pharmacometrics : the science of quantitative pharmacology , 2007 .

[8]  Marc Pfister,et al.  Concepts and Challenges in Quantitative Pharmacology and Model-Based Drug Development , 2008, The AAPS Journal.

[9]  H. Lowman,et al.  Use of Quantitative Pharmacology in the Development of HAE1, a High-Affinity Anti-IgE Monoclonal Antibody , 2008, The AAPS Journal.

[10]  Adam Cohen,et al.  Pharmacokinetic and Pharmacodynamic Data to be Derived from Early-Phase Drug Development , 2008, Clinical pharmacokinetics.

[11]  William J Jusko,et al.  Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. , 2009, Drug metabolism and pharmacokinetics.

[12]  Lawrence J Lesko,et al.  Quantitative disease, drug, and trial models. , 2009, Annual review of pharmacology and toxicology.

[13]  Meindert Danhof,et al.  Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling. , 2009, Drug metabolism and pharmacokinetics.

[14]  T. Kenakin.  Cellular assays as portals to seven-transmembrane receptor-based drug discovery , 2009, Nature Reviews Drug Discovery.

[15]  Johan Gabrielsson,et al.  Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development. , 2009, Future medicinal chemistry.

[16]  B. Munos.  Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.

[17]  Johan Gabrielsson,et al.  Optimising in vivo pharmacology studies--Practical PKPD considerations. , 2010, Journal of pharmacological and toxicological methods.

[18]  N. Benson,et al.  Translational pharmacokinetic-pharmacodynamic modelling; application to cardiovascular safety data for PF-00821385, a novel HIV agent. , 2010, British journal of clinical pharmacology.

[19]  Maciej Swat,et al.  What it takes to understand and cure a living system: computational systems biology and a systems biology-driven pharmacokinetics–pharmacodynamics platform , 2011, Interface Focus.

[20]  D. Noble,et al.  Systems Biology: An Approach , 2010, Clinical pharmacology and therapeutics.

[21]  Päivi Heikkilä,et al.  Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies , 2010, PLoS medicine.

[22]  Jan van den Berg,et al.  Systems Biology and Pharmacology , 2010, Clinical pharmacology and therapeutics.

[23]  D. Howells,et al.  Can Animal Models of Disease Reliably Inform Human Studies? , 2010, PLoS medicine.

[24]  Michael Rowley,et al.  Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry. , 2011, Current topics in medicinal chemistry.

[25]  Gianne Derks,et al.  Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency. , 2011, Journal of theoretical biology.